PortalPublikationenPredictive Factors for Outcome of First Allogeneic Transplan...

Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia

Standard

Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia. / Bazarbachi, Abdul Hamid; Labopin, Myriam; Kröger, Nicolaus; Brecht, Arne; Blaise, Didier; Clausen, Johannes; Fanin, Renato; Einsele, Herman; Cavanna, Luigi; Itäla-Remes, Maija; Bulabois, Claude Eric; Kündgen, Lukas; Martin, Hans; Schmid, Christof; Wagner-Drouet, Eva Maria; Alakel, Nael; Bazarbachi, Ali; Savani, Bipin; Nagler, Arnon; Mohty, Mohamad.

in: CL LYMPH MYELOM LEUK, Jahrgang 21, Nr. 12, 12.2021, S. 831-840.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Bazarbachi, AH, Labopin, M, Kröger, N, Brecht, A, Blaise, D, Clausen, J, Fanin, R, Einsele, H, Cavanna, L, Itäla-Remes, M, Bulabois, CE, Kündgen, L, Martin, H, Schmid, C, Wagner-Drouet, EM, Alakel, N, Bazarbachi, A, Savani, B, Nagler, A & Mohty, M 2021, 'Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia', CL LYMPH MYELOM LEUK, Jg. 21, Nr. 12, S. 831-840. https://doi.org/10.1016/j.clml.2021.07.010

APA

Bazarbachi, A. H., Labopin, M., Kröger, N., Brecht, A., Blaise, D., Clausen, J., Fanin, R., Einsele, H., Cavanna, L., Itäla-Remes, M., Bulabois, C. E., Kündgen, L., Martin, H., Schmid, C., Wagner-Drouet, E. M., Alakel, N., Bazarbachi, A., Savani, B., Nagler, A., & Mohty, M. (2021). Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia. CL LYMPH MYELOM LEUK, 21(12), 831-840. https://doi.org/10.1016/j.clml.2021.07.010

Vancouver

Bazarbachi AH, Labopin M, Kröger N, Brecht A, Blaise D, Clausen J et al. Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia. CL LYMPH MYELOM LEUK. 2021 Dez;21(12):831-840. https://doi.org/10.1016/j.clml.2021.07.010

Bibtex

@article{380434a514a3479597b37c79063b53c1,
title = "Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia",
abstract = "INTRODUCTION/BACKGROUND: The treatment of acute lymphoblastic leukemia (ALL) in patients older than 70 is extremely challenging with dismal outcome. Allogeneic stem cell transplantation (alloHCT) has seen many advancements in the last decades showing benefits in younger ALL patients, but this treatment modality is decreasingly used with increasing age due to high treatment-related mortality.PATIENTS AND METHODS: We identified 84 ALL patients 70 to 84 years old allografted In 2002 to 2019 from a matched related (23%), unrelated (58%), haploidentical (17%), or cord blood (2%) donor at EBMT participating centers with a median follow-up of 23 months.RESULTS: The 2-year relapse incidence (RI) and non-relapse mortality were 37% and 28%, respectively, and 2-year leukemia-free survival (LFS), overall survival (OS) and GVHD-free, relapse-free survival (GRFS) were 35%, 39% and 23%, respectively. The strongest predictor of outcome was disease status at transplant whereby patients in first complete remission (CR1) had >50% 2-year OS, reflected in multivariate analysis (MVA) with significant improvement in RI, LFS, and GRFS (HR 0.23, 0.49, and 0.54, respectively). Furthermore, karnofsky score ≥90 reflective of good functional status positively influenced non-relapse mortality in both univariate and MVA (HR 0.37), and interestingly, donor CMV positivity appeared to negatively affect RI, LFS and OS in univariate analysis and RI in MVA (HR 2.87).CONCLUSION: Our data suggest that alloHCT is an option for elderly ALL patients, particularly those carefully selected and transplanted in CR1 especially if failed or without access to novel non-chemotherapy-based approaches.",
author = "Bazarbachi, {Abdul Hamid} and Myriam Labopin and Nicolaus Kr{\"o}ger and Arne Brecht and Didier Blaise and Johannes Clausen and Renato Fanin and Herman Einsele and Luigi Cavanna and Maija It{\"a}la-Remes and Bulabois, {Claude Eric} and Lukas K{\"u}ndgen and Hans Martin and Christof Schmid and Wagner-Drouet, {Eva Maria} and Nael Alakel and Ali Bazarbachi and Bipin Savani and Arnon Nagler and Mohamad Mohty",
note = "Copyright {\textcopyright} 2021. Published by Elsevier Inc.",
year = "2021",
month = dec,
doi = "10.1016/j.clml.2021.07.010",
language = "English",
volume = "21",
pages = "831--840",
journal = "CL LYMPH MYELOM LEUK",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "12",

}

RIS

TY - JOUR

T1 - Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia

AU - Bazarbachi, Abdul Hamid

AU - Labopin, Myriam

AU - Kröger, Nicolaus

AU - Brecht, Arne

AU - Blaise, Didier

AU - Clausen, Johannes

AU - Fanin, Renato

AU - Einsele, Herman

AU - Cavanna, Luigi

AU - Itäla-Remes, Maija

AU - Bulabois, Claude Eric

AU - Kündgen, Lukas

AU - Martin, Hans

AU - Schmid, Christof

AU - Wagner-Drouet, Eva Maria

AU - Alakel, Nael

AU - Bazarbachi, Ali

AU - Savani, Bipin

AU - Nagler, Arnon

AU - Mohty, Mohamad

N1 - Copyright © 2021. Published by Elsevier Inc.

PY - 2021/12

Y1 - 2021/12

N2 - INTRODUCTION/BACKGROUND: The treatment of acute lymphoblastic leukemia (ALL) in patients older than 70 is extremely challenging with dismal outcome. Allogeneic stem cell transplantation (alloHCT) has seen many advancements in the last decades showing benefits in younger ALL patients, but this treatment modality is decreasingly used with increasing age due to high treatment-related mortality.PATIENTS AND METHODS: We identified 84 ALL patients 70 to 84 years old allografted In 2002 to 2019 from a matched related (23%), unrelated (58%), haploidentical (17%), or cord blood (2%) donor at EBMT participating centers with a median follow-up of 23 months.RESULTS: The 2-year relapse incidence (RI) and non-relapse mortality were 37% and 28%, respectively, and 2-year leukemia-free survival (LFS), overall survival (OS) and GVHD-free, relapse-free survival (GRFS) were 35%, 39% and 23%, respectively. The strongest predictor of outcome was disease status at transplant whereby patients in first complete remission (CR1) had >50% 2-year OS, reflected in multivariate analysis (MVA) with significant improvement in RI, LFS, and GRFS (HR 0.23, 0.49, and 0.54, respectively). Furthermore, karnofsky score ≥90 reflective of good functional status positively influenced non-relapse mortality in both univariate and MVA (HR 0.37), and interestingly, donor CMV positivity appeared to negatively affect RI, LFS and OS in univariate analysis and RI in MVA (HR 2.87).CONCLUSION: Our data suggest that alloHCT is an option for elderly ALL patients, particularly those carefully selected and transplanted in CR1 especially if failed or without access to novel non-chemotherapy-based approaches.

AB - INTRODUCTION/BACKGROUND: The treatment of acute lymphoblastic leukemia (ALL) in patients older than 70 is extremely challenging with dismal outcome. Allogeneic stem cell transplantation (alloHCT) has seen many advancements in the last decades showing benefits in younger ALL patients, but this treatment modality is decreasingly used with increasing age due to high treatment-related mortality.PATIENTS AND METHODS: We identified 84 ALL patients 70 to 84 years old allografted In 2002 to 2019 from a matched related (23%), unrelated (58%), haploidentical (17%), or cord blood (2%) donor at EBMT participating centers with a median follow-up of 23 months.RESULTS: The 2-year relapse incidence (RI) and non-relapse mortality were 37% and 28%, respectively, and 2-year leukemia-free survival (LFS), overall survival (OS) and GVHD-free, relapse-free survival (GRFS) were 35%, 39% and 23%, respectively. The strongest predictor of outcome was disease status at transplant whereby patients in first complete remission (CR1) had >50% 2-year OS, reflected in multivariate analysis (MVA) with significant improvement in RI, LFS, and GRFS (HR 0.23, 0.49, and 0.54, respectively). Furthermore, karnofsky score ≥90 reflective of good functional status positively influenced non-relapse mortality in both univariate and MVA (HR 0.37), and interestingly, donor CMV positivity appeared to negatively affect RI, LFS and OS in univariate analysis and RI in MVA (HR 2.87).CONCLUSION: Our data suggest that alloHCT is an option for elderly ALL patients, particularly those carefully selected and transplanted in CR1 especially if failed or without access to novel non-chemotherapy-based approaches.

U2 - 10.1016/j.clml.2021.07.010

DO - 10.1016/j.clml.2021.07.010

M3 - SCORING: Journal article

C2 - 34373225

VL - 21

SP - 831

EP - 840

JO - CL LYMPH MYELOM LEUK

JF - CL LYMPH MYELOM LEUK

SN - 2152-2650

IS - 12

ER -